LUA TECHNOLOGIES, A SUBSIDIARY OF LIFE BIOSCIENCES, RATED AS THE LEADING POST-ACUTE SECURE MESSAGING SOLUTION BY KLAS RESEARCH* Top Healthcare Data and Insights Company Uses Impartial Research for Key Industry Reports Used by Providers and Payers Worldwide BOSTON, February 14 –Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure … Continued
Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA. Orphan Drug … Continued
BOSTON, Jan. 15, 2019 /PRNewswire/ — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ … Continued
FOR IMMEDIATE RELEASE SENOLYTIC THERAPEUTICS KICKS OFF Q1 2019 WITH HIGH-PROFILE SPEAKING EVENTS FEATURING CO-FOUNDERS MARC RAMIS AND MANUEL SERRANO Barcelona-Based Biotech is a Daughter Company of Life Biosciences Funded and Supported by Pioneer in the Study of Age-Related Decline BOSTON, JANUARY 9 — Senolytic Therapeutics, an innovator in senescent cell research and one … Continued
MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 28 December 2018: Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) (“Prana” or “the Company”) has today announced that it has entered into a securities purchase agreement for a lead investment by Boston based Life Biosciences LLC (“Life Biosciences”) to raise up to approximately A$44.5 million (approx. US$31.4 million). … Continued
